Results 181 to 190 of about 131,732 (302)

Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors with improved selectivity and solubility. [PDF]

Acta Pharm Sin B, 2023
Zhao LM, Pannecouque C, Clercq E, Wang S, Chen FE.   +4 more
europepmc   +1 more source

Targeting eIF5A combats breast cancer progression by ClpP‐dependent mitochondrial oxidative stress

Interdisciplinary Medicine, EarlyView.
This study identified the eIF5A‐ClpP axis as a key driver of breast cancer progression. Targeting eIF5A suppresses tumor growth by inducing ClpP‐dependent mitochondrial oxidative stress, revealing a novel therapeutic vulnerability. Abstract Breast cancer (BC) poses a persistent global health challenge, necessitating new therapeutic targets.
Jinmei Zhu, Baoyuan Tang, Bei Xie, Haohua Deng, Haitang Yang, Lei Ma, Ziqing Zhang, Yicheng Ma, Xingyuan Ma, Shuaiyang Wang, Jing Li, Lei Zhao, Wengui Shi, Linjing Li   +13 more
wiley   +1 more source

Discovery of Dual Targeting GSK-3β/HIV-1 Reverse Transcriptase Inhibitors as Neuroprotective Antiviral Agents. [PDF]

ACS Chem Neurosci
Jones T, Raman R, Puhl AC, Lane TR, Riabova O, Kazakova E, Makarov V, Ekins S.   +7 more
europepmc   +1 more source

Identification of Boronate-Containing Diarylpyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. [PDF]

Molecules, 2022
Feng D, Lin H, Jiang L, Wang Z, Sun Y, Zhou Z, Clercq E, Pannecouque C, Kang D, Zhan P, Liu X.   +10 more
europepmc   +1 more source

Integrated one‐pot CRISPR‐Cas detection: Addressing strategies and future prospects

Interdisciplinary Medicine, EarlyView.
Integrated one‐pot CRISPR‐Cas detection significantly simplifies workflows, reduces cross‐contamination risks, and shortens turnaround times, making it highly suitable for point‐of‐care testing (POCT) and resource‐limited settings. Key challenges include system compatibility issues between Cas proteins and isothermal amplification, limited multiplexing
Jian Zhou, Xuemei Ren, Yingjie Ren, Ruiping Wu, Ruiman Geng, Le Chen, Zhuo Li   +6 more
wiley   +1 more source

Synthesis of novel N1 functionalized diazepinone analogues <i>via</i> a base-mediated C-N cross coupling reaction as reverse transcriptase inhibitors: theoretical and experimental investigations. [PDF]

RSC Adv
Jaiswal S, Jain S, Mukhija A, Verma K, Jain S, Kishore D, Dwivedi J, Sharma S.   +7 more
europepmc   +1 more source

Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi. [PDF]

Antivir Ther, 2022
Bello G, Kagoli M, Chipeta S, Auld A, Chang JC, DeVos JR, Kim E, Mkungudza J, Payne D, Eliya M, Nyirenda R, Jahn A, Mzumara T, Mvula B, Dadabhai S, Namakhoma I, Babaye Y, Giron A, Jordan MR, Bertagnolio S, O'Malley G, Wadonda-Kabondo N.   +21 more
europepmc   +1 more source

Enhanced CRISPR‐cas systems for genome editing and molecular diagnostics

Interdisciplinary Medicine, EarlyView.
This review systematically summarizes the major optimization strategies for CRISPR‐Cas systems, focusing on the engineering of Cas proteins, guide RNAs, reporter probes, and the incorporation of chemical additives. The aim is to enhance editing precision and diagnostic capability, thereby expanding the CRISPR system's potential for broader biomedical ...
Sheng Li, Han Li, Bojie Chen, Ling Jiang, Keyu Long, Jiaqi Lang, Xingxiang Pu, Erhu Xiong   +7 more
wiley   +1 more source

Reverse transcriptase activity in psoriatic lesions: effects of reverse transcriptase inhibitors on keratinocyte proliferation and differentiation

Retrovirology, 2009
Bonté Frédéric, Dumas Marc, Tesniere Anne, Molès Jean-Pierre, Guilhou J-J   +4 more
doaj   +1 more source

Identification of Novel Diarylpyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors by Exploring the Primer Grip Region. [PDF]

Pharmaceuticals (Basel), 2022
Zhang T, Zhou Z, Zhao F, Sang Z, De Clercq E, Pannecouque C, Kang D, Zhan P, Liu X.   +8 more
europepmc   +1 more source